Article Contents ::
- 1 The Brand Name INFULID Has Generic Salt :: Linezolid
- 2 INFULID Is From Company NEISS Priced :: Rs. 315
- 3 INFULID have Linezolid is comes under Sub class Miscellaneous of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name INFULID Has Generic Salt :: Linezolid
INFULID Is From Company NEISS Priced :: Rs. 315
INFULID have Linezolid is comes under Sub class Miscellaneous of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Community-acquired pneumonia, Skin and skin structure infections, Nosocomial pneumonia
Drug Dose ::
Adults and Adolescents (12 Years and Older): PO Uncomplicated skin infections 400 mg 12 hrly for 10-14 days. PO/IV Community-acquired pneumonia; Complicated skin and skin structure infections; Nosocomial pneumonia 600 mg 12 hrly for 10-14 days. For Pediatric Patients (Birth through 11 Years of Age): • Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV or oral b.i.d. for 10 to 14 days. • Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV or oral b.i.d.for 14-28. Neonates < 7 days: Most pre-term neonates < 7 days of age (gestational age < 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg in every eight hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg t.i.d. by 7 days of life. Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococci infections 600 mg 12 hrly. Treatment duration for vancomycin-resistant enterococci: 14-28 day. Contraindication ::
Drug Precautions ::
Preexisting myelosuppression, renal impairment (CrCl < 30ml/min), uncontrolled hypertension, phaeochromocytoma, carcinoid syndrome, untreated hyperthyroidism, chronic infection, history of seizures, bipolar depression, schizophrenia or acute confusional states. Pregnancy and lactation. Monitor complete blood counts weekly. Give after haemodialysis. Not known if linezolid or metabolites removed during peritoneal dialysis. Drug Side Effects ::
Diarrhoea (antibiotic associated colitis reported), headache, nausea, vomiting, constipation, abnormal liver function tests, fever, vaginal and oral candidiasis, skin rash, pruritus, dizziness, insomnia, anaemia, tongue discoloration, taste disturbance, lactic acidosis, optic and peripheral neuropathy (particularly if used > 28 days). Potentially Fatal: Reversible myelosuppression including anaemia, leukopenia, pancytopenia and thrombocytopenia (particularly if using > 10-14 days), transient ischaemic attacks, renal failure, Stevens-Johnson syndrome.
Pregnancy category ::
Drug Mode of Action ::
Linezolid is a bacteriostatic oxazolidinone which acts by inhibiting ribosomal protein synthesis. It is active against gm+ve bacteria including vancomycin-resistant enterococci and MRSA. It has limited in vitro activity against gm-ve bacteria.
Drug Interactions ::
May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol. Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).